Mike Murray, Ph.D., leads strategic business development in Europe and the U.S. government sector for the Drug Development division. His responsibilities include developing strategic business relationships with key decision makers, including executive management, establishing new relationships with industry partners, and linking government agency scientific requirements with expertise and solutions provided by Southern Research’s internationally recognized teams.
Murray represents highly dedicated and experienced science leaders working to develop cures for various cancers and infectious diseases. The Drug Development team provides toxicology, bioanalytical, immunology, consulting, non-clinical and clinical trial support services including an array of in vitro and in vivo testing of small molecules, biologics and vaccine test articles for private industry and government agencies.
Murray joined Southern Research with experience in academia, biotech and the pharmaceutical industry. Since joining Southern Research, he has developed a broad knowledge of Southern Research capabilities and the mission objectives of multiple government organizations addressing public health problems.
Prior to his business development role, Murray directed SR’s infectious disease research site in Frederick Maryland, where he was responsible for scientific leadership, financial performance, compliance, and go/no-go decision making. Murray served as principle investigator for National Institutes of Health and the Biomedical Advanced Research and Development Authority prime contracts supporting the HIV cure initiative, as well as the discovery of inhibitors for viral threats to public health including hepatitis B & C, influenza, Ebola, poliovirus, and bio-threat agents.
Prior to Southern Research, Murray developed antivirals at Schering-Plough (now Merck) where he played a key role in the discovery and development of Vicriviroc®, a CCR5 co-receptor antagonist HIV inhibitor and Boceprivir (now Victrelis®), an HCV protease inhibitor.
Murray earned a doctorate in molecular microbiology at Stony Brook University School of Medicine in New York, and he completed post-doctoral training at Repligen Corporation in Cambridge, Massachusetts. He is author of more than 39 scientific publications, and has provided numerous speaking presentations in the U.S., Italy, China, and Japan.